Published in Medical Letter on the CDC and FDA, March 12th, 2006
In addition, the company announced that it has completed 3-month animal toxicology studies that will support clinical studies of VX-950 of up to 3 months duration.
Initiation of additional phase 2 clinical studies in the U.S. in patients with HCV is planned following required Food and Drug Administration (FDA) review of these latest nonclinical and clinical results, and FDA review of a proposed clinical study protocol. This information will be submitted to the FDA within the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA